Checkpoint inhibitors

Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 19, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Stage III and Stage IV Mycosis Fungoides and Sézary Syndrome / Treatment Options for Stage III and Stage IV Mycosis Fungoides and Sézary Syndrome

Pembrolizumab.[52]

Source links and citations

Pembrolizumab.[52]

Anecdotal responses have been seen in patients with advanced relapsed or refractory mycosis fungoides. In a single-arm, multicenter, phase II trial of 24 patients treated with pembrolizumab, the overall response rate was 38%.[52][Level of evidence C3]

Source links and citations

Pembrolizumab.[52]

There are anecdotal reports of hyperprogression of T-cell malignancies following treatment with immune checkpoint inhibitors.[53,54]

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice